Highlights

So, the standard of care would include EGFR, ALK, ROS, RET, NTRK, etc, but we do a lot of other testing, P53 and a couple of other resistant mutations etc. In total, about 40 different genes, NR fusions, and methylation patterns, and amplifications.

Absolutely, in our approval in our country, you do IO mono in patients who had a PD-L1 expression level above 50%. You do a combination with chemo in patients who have both PD-L1 expression more than 1% or no expression. For patients who have no expression, we look at certain kinds of molecular alterations, if we think it is worthwhile to add IO to the therapeutic option, we do in those patients, in particular in patients who have no PD-L1 expression, and no TTF1 expression, we do see that as a specific entity, which does not have a higher benefit of using either pemetrexed or IO.

There is no clear benefit in adding chemo to IO. We choose monotherapy in patients who are elderly, frail, patients who do not like to have any kind of chemo, so they would be selected for IO monotherapy. In some patients, where we believe there is a high tumor burden, and we would like to combine that with the option of doing radiotherapy early on, and we do a combination of adding chemo to IO.